AUPH
Aurinia Pharma
–
Index: NASDAQ; Sector: ; Industry: ;
Marketcap: 1.68B; Volume: 162.25K; AvgVol 3m: 1.50M; Beta: –;
Cost estimate:
P/E: –; EPS: –; EPS growth quarter/prev quarter: ;
EPS growth this year: -53.00%; EPS growth past 5 years: ;
EPS ttm: -1.37;
P/S: 6042.63; P/B: 7.18; P/Cashflow: ; P/FCF: ;
Sales: 320.00K; Sales growth quarter/prev quarter: 0.00%; Sales growth past 5 years: ;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: ; ROE – return on equity: ; LT Debt/Equity: ; Total Debt/Equity: ;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 17.11%; Insider Transactions:0.00%;
Institutional Ownership: 49.68%; Institutional Transactions: ;
Data update: 07/10/2020.